Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 7:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Selective Serotonin Reuptake Inhibitor Clear all
Completed Phase 4 Interventional Results available

Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.

NCT01148979
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lisdexamfetamine Dimesylate (Vyvanse), Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jul 23, 2026, 7:59 AM EDT
Recruiting Not applicable Interventional

Biomarkers in the Retina for Prognosticating Mental Health Treatments

NCT06363968
View directory record Official record
Conditions
PTSD, Posttraumatic Stress Disorder
Interventions
RETeval
Device
Lead sponsor
VA Puget Sound Health Care System
Federal
Eligibility
21 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Jul 23, 2026, 7:59 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Impact of Depression on Thermoregulation

NCT06805851
View directory record Official record
Conditions
Depression, Selective Serotonin Reuptake Inhibitor
Interventions
Not listed
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 40 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Jul 23, 2026, 7:59 AM EDT
Terminated Phase 3 Interventional Results available

12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress

NCT01040208
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological, Depression
Interventions
flibanserin 50 mg to 100 mg qhs, flibanserin 100 mg qhs, placebo 2 tablets qhs
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
42
States / cities
Costa Mesa, California • Fresno, California • National City, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2016 · Synced Jul 23, 2026, 7:59 AM EDT
Completed Phase 4 Interventional

Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo

NCT00334048
View directory record Official record
Conditions
Sexual Dysfunction
Interventions
Ropinirole (Requip)
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Jul 23, 2026, 7:59 AM EDT
Completed Phase 4 Interventional Results available

Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder

NCT00955955
View directory record Official record
Conditions
Depression
Interventions
6(S)-5-MTHF(Deplin), Placebo
Other
Lead sponsor
George I. Papakostas
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
San Diego, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Jul 23, 2026, 7:59 AM EDT
Not listed Not applicable Interventional

A Viveve Experience Normalizes Untreated Selective Serotonin Reuptake Inhibitor (SSRI) Sexuality Syndrome

NCT03679702
View directory record Official record
Conditions
Sexual Dysfunction
Interventions
Viveve System
Device
Lead sponsor
Michael Krychman, MD
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Jul 23, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

NCT00840034
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
LY2216684, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Carson, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Jul 23, 2026, 7:59 AM EDT
Terminated No phase listed Observational

A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant

NCT05109195
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Standard of Care (SOC)
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
San Francisco, California • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Jul 23, 2026, 7:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

NCT02134808
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Creatine, Placebo
Drug
Lead sponsor
Perry Renshaw
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jul 23, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

NCT01187407
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
LY2216684, Placebo, SSRI
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chino, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Jul 23, 2026, 7:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glutamate Probes in Adolescent Depression

NCT02307617
View directory record Official record
Conditions
Major Depressive Disorder, Major Depressive Disorder, Recurrent, Major Depressive Disorder, Remitted
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
13 Years to 21 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Jul 23, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression

NCT00093847
View directory record Official record
Conditions
Depression
Interventions
S-adenosyl methione (SAMe), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 12, 2014 · Synced Jul 23, 2026, 7:59 AM EDT
Completed Phase 2Phase 3 Interventional

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

NCT01318434
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
EB-1010 25mg BID, SSRI Active, EB-1010 50mg BID, Placebo
Drug
Lead sponsor
Euthymics BioScience, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
43
States / cities
Arcadia, California • Beverly Hills, California • National City, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Jul 23, 2026, 7:59 AM EDT
Completed Not applicable Interventional

Efficacy of Exercise for Sexual Side Effects of Antidepressants

NCT01189825
View directory record Official record
Conditions
Sexual Dysfunction
Interventions
Exercise
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Jul 23, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Safety Study of AXS-05 in Subjects With Depression

NCT04039022
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression, Depression
Interventions
AXS-05 (dextromethorphan and bupropion) oral tablets
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
51
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced Jul 23, 2026, 7:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women

NCT00894543
View directory record Official record
Conditions
Hot Flashes, Menopause, Vasomotor Symptoms
Interventions
Escitalopram, Placebo
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Oakland, California • Indianapolis, Indiana • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Jul 23, 2026, 7:59 AM EDT
Terminated Phase 2 Interventional Results available

Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder

NCT01103180
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Escitalopram
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Jul 23, 2026, 7:59 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Partners in Caring for Anxious Youth

NCT04598230
View directory record Official record
Conditions
Anxiety, Separation, Anxiety, Generalized, Anxiety, Social
Interventions
Cognitive Behavioral Therapy (CBT), Combination therapy (COMB)
Behavioral · Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
7 Years to 17 Years
Enrollment
468 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 23, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs

NCT00633399
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Birmingham, Alabama • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Jul 23, 2026, 7:59 AM EDT
Completed Phase 4 Interventional

A Study of 6(S)-5-MTHF Among Serotonin Reuptake Inhibitor(SSRI)-Resistant Outpatients With Major Depressive Disorder (MDD)

NCT00321152
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
6(S)-5-MTHF (a Medical Food)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
11
States / cities
San Diego, California • Chicago, Illinois • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2010 · Synced Jul 23, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

A Safety Study in Participants With Major Depressive Disorder

NCT01155661
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
LY2216684 (edivoxetine), SSRI
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Jul 23, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder

NCT00523718
View directory record Official record
Conditions
Obsessive-compulsive Disorder, Ocd
Interventions
riluzole, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Jul 23, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

NCT01364649
View directory record Official record
Conditions
Treatment Outcome
Interventions
Vortioxetine, Escitalopram, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
53
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Jul 23, 2026, 7:59 AM EDT